Analyzing clinical follow up yielded CLDN3 loss of expression implied a lower disease-free survival and time to clinical progression (Figure 6C), indicating that CLDN3 expression can predict the prognosis of prostate cancer patients. This evidence concerns the gene CLDN3 and prostate cancer.